# HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

> **NCT03326921** · PHASE1 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Juvenile Myelomonocytic Leukemia
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Undifferentiated Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Adult Acute Lymphoblastic Leukemia
- Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Myelodysplastic Syndrome
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Myelodysplastic Syndrome
- Acute Undifferentiated Leukemia
- Mixed Phenotype Acute Leukemia
- Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Biphenotypic Leukemia
- Chronic Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Minimal Residual Disease
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Mixed Phenotype Acute Leukemia
- Leukemia
- Chronic Myeloid Leukemia, BCR-ABL1 Positive

## Interventions

- **BIOLOGICAL:** CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT03326921
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-23
- **Primary completion:** 2027-10-16
- **Final completion:** 2028-07-16
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326921, "HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03326921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*